Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21224
Submitted 27 November 2001 ; accepted in final form 24 February 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
thrombin; extracellular signal-regulated kinase; caldesmon; transendothelial electrical resistance
Edemagenic factors such as the serine protease thrombin, generated during activation of the coagulation cascade, directly increase vascular permeability in vivo and in vitro (14, 36), indicating the relevance of in vitro models of thrombin-induced endothelial cell permeability. Thrombin induces endothelial cell activation and cellular responses via activation of its G protein-coupled receptors, increases intracellular Ca2+ as a direct result of phospholipase C activation, and increases phospholipase A2, phospholipase D, and protein kinase C activities (16, 19, 27). These signals result in the rearrangement of the endothelial actin cytoskeleton. We have previously shown a critical role for MLCK activation and MLC phosphorylation in thrombin-induced actin cytoskeleton rearrangement, gap formation, and increases in endothelial cell permeability (15). However, contractile forces in this model of endothelial cell permeability are unlikely to be entirely modulated by MLCK-dependent mechanisms of endothelial cell contraction. This is suggested by the reproducible observation that the time response curve of thrombin-mediated permeability and MLC phosphorylation is not tightly correlative, with a relatively sustained level of permeability while MLC phosphorylation is decreasing (15), findings reminiscent of the latch state postulated to exist in slowly contracting smooth muscle.
One potential MLCK-independent contractile mechanism may involve the cytoskeletal protein caldesmon, a major actin-, myosin-, tropomyosin-, and calmodulinbinding protein, which is involved in the regulation of smooth muscle and nonmuscle contraction (46). Caldesmon is expressed from a single gene and spliced to yield either a high-molecular-weight smooth musclespecific isoform (120150 kDa) or a low-molecular-weight (7080 kDa) isoform, widely distributed in nonmuscle cells (46). Caldesmon exhibits inhibitory function toward actin-tropomyosin-activated myosin ATPase activity, which can be reversed by calmodulin (CaM) binding in a Ca2+-dependent manner and/or by Ser/Thr phosphorylation (37). Caldesmon can be phosphorylated by CaM kinase II, a multifunctional Ca2+/CaM-dependent Ser/Thr protein kinase, with phosphorylation sites at both NH2 and COOH termini (30), and by extracellular signal-regulated kinases (ERK) at two major COOH terminus sites, Ser759 and Ser789 (2, 9), based on the numbering of the mammalian high-molecular-weight caldesmon sequence (29). Phosphorylation of smooth muscle caldesmon by CaM kinase II leads to dissociation of myosin from caldesmon, reduces the binding of caldesmon to actin, and reverses inhibition of the myosin Mg2+-ATPase (26, 39, 40, 47). The effect of phosphorylation of smooth muscle caldesmon by ERK is less well understood but reported to slightly attenuate its interaction with actin (8) and to release actomyosin interaction (10, 21, 22, 52). These studies in smooth muscle using high-molecular-weight caldesmon isoforms are applicable to nonmuscle cells, given the close structural and functional relationship between the caldesmon isoforms. In nonmuscle cells, caldesmon cross-links actin and myosin and is involved in cell contractility, cell division, assembly of actin stress fibers, and interferes with the formation of focal adhesions (7, 23, 25, 46, 55, 57).
We recently reported that thrombin-induced CaM kinase II activation modulates endothelial cell permeability in an MLCK-independent fashion (5), analogous to smooth muscle thin filament-dependent contractile regulation (12). Phosphorylation by CaM kinase II alters the function of a variety of substrates (6), including MAPK (ERK) activities (1). This is of particular interest since we have shown that ERK activation occurs via sequential Ras, Raf-1, and MEK activities and regulates phorbol ester-induced endothelial cell barrier dysfunction (50). However, the interrelationship between ERK and CaM kinase II activities in thrombin-mediated endothelial cell permeability remains unclear.
In the present study, we examined this linkage and explored the role of caldesmon, a potential cytoskeletal target in thrombin-stimulated signaling pathways. Our data indicate that ERK activation is involved in endothelial cell permeability induced by thrombin and proceeds in a CaM kinase II-dependent fashion. CaM kinase II/ERK inhibition attenuates thrombin-induced phosphorylation of caldesmon and reverses thrombin-induced dissociation of caldesmon-myosin complex. Furthermore, the inhibition of the CaM kinase II/ERK signaling pathway leads to impairment of thrombin-induced stress fiber formation and attenuated endothelial cell barrier dysfunction. These results provide new insights into nonmuscle contractile regulation and endothelial barrier regulation.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cell culture. Bovine pulmonary artery endothelial cells were obtained frozen at 16 passages from American Type Culture Collection (CCL 209; Manassas, VA) and were utilized at passages 1924. Endothelial cells were cultured in complete media and maintained at 37°C in a humidified atmosphere of 5% CO2-95% air and grew to contact-inhibited monolayers with the typical cobblestone morphology. Cells from each primary flask were detached with 0.05% trypsin and resuspended in fresh culture medium and passaged to the appropriate size flasks or dishes.
Transendothelial electrical resistance. Endothelial cells were seeded onto evaporated gold microelectrodes and grown to confluence as we have previously described (20). Endothelial cells formed a confluent monolayer that covered the microelectrodes connected to an electrical cell-substrate impedance system (Applied Biophysics, Troy, NY). Resistance values from each microelectrode (measured in ohms) were normalized as the ratio of measured resistance to baseline resistance and plotted vs. time.
Western immunoblotting and immunoprecipitation of caldesmon. After
being treated, endothelial cell monolayers grown in 35-mm dishes were rinsed
with ice-cold PBS, lysed with 2x SDS sample buffer, and boiled for 5
min. Extracts were separated on SDS-PAGE, transferred to nitrocellulose (30 V,
18 h), and reacted with antibody of interest. Immunoreactive proteins were
visualized using an enhanced chemiluminescent detection system. The relative
intensities of the protein bands were quantified by scanning densitometry. The
comparisons of two means were performed using Student's t-test.
Differences in two groups are considered statistically significant when
P < 0.05. For immunoprecipitation under either denaturing or
nondenaturing conditions, confluent endothelial cells (106)
were rinsed with PBS, then lysed with the addition of either boiling lysis
buffer (1% SDS, 1 mM sodium vanadate, 10 mM Tris · HCl, pH 7.4) or
ice-cold immunoprecipitation buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris,
pH 7.4, 1 mM EDTA, 1 mM EGTA, 0.5% Nonidet P-40, and protease inhibitors). A
total of 20 µl of protein G-Agarose (Calbiochem), 400 µl of
H2O, 400 µl of immunoprecipitation buffer, and 100 µl of
total endothelial cell lysate were combined and incubated for 30 min at
4°C, followed by centrifugation for 5 min. The supernatant fraction was
retrieved, and 1020 µg of monoclonal antibody to caldesmon was added
and incubated for 1 h at 4°C. Approximately 2030 µl of protein
G-Agarose was added to each tube and incubated for additional 30 min, followed
by centrifugation for 1 min. Pellets were washed three times with
immunoprecipitation buffer, resuspended in 2x SDS sample buffer, and
boiled for 5 min. Samples were subjected onto SDS-PAGE, transferred to
nitrocellulose (30 V, 18 h), and analyzed by Western immunoblotting.
Detection of caldesmon phosphorylation. Thrombin-induced caldesmon phosphorylation was assessed either in caldesmon immunoprecipitates obtained from 32P-labeled endothelial cells or using previously characterized (9, 10, 13) phosphospecific anti-caldesmon antibodies raised against peptide sequences surrounding the two major ERK-catalyzed phosphorylation sites: Ser759 [PDGNKS(PO4)PAPKPGC] and Ser789 [CQSVDKVTS(PO4)PTKV], based on the numbering of the human high-molecular-weight caldesmon sequence (29).
MLC phosphorylation. Endothelial cell MLC phosphorylation was analyzed by SDS-PAGE followed by Western immunoblotting with diphosphospecific anti-MLC antibodies as we have recently reported (42).
Endothelial cell transfection with adenovirus encoding constitutively
active -CaM kinase II. A cDNA for constitutively active
mutant of
-CaM kinase II (generated by site-directed mutagenesis of
amino acids Thr286 and Val287 to aspartic acid) was
placed downstream of a cytomegalovirus (CMV) promoter in a
replication-deficient adenovirus as described
(3). An adenovirus with CMV
promoter but without insertion was used as a control for infection. Cultured
endothelial cells at 7080% confluency were exposed to either
recombinant or control adenovirus at 580 multiplicities of infection
(MOI) for 1 h in DMEM (GIBCO BRL) containing 2% FBS. The virus-containing
medium was then replaced with virus-free DMEM with 10% FBS, and endothelial
cells were analyzed after 30 h.
Preparation of subcellular fractions. Bovine pulmonary artery endothelial cells (80100%) were fractionated into cytosolic, membrane, and nuclear/cytoskeleton fractions as previously described (43). Cells were rinsed with PBS and incubated in ice-cold cytosolic buffer (0.01% digitonin, 10 mM PIPES, pH 6.8, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 5 mM EDTA, 5 µM phallicidin) and protease inhibitory cocktail (1:500 diluted, Calbiochem) with agitation for 10 min at 4°C. Soluble cytosolic fraction was collected, dishes were rinsed with cytosolic buffer without protease inhibitors, and the residual material was extracted with membrane buffer (0.5% Triton X-100, 10 mM PIPES, pH 7.4, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 3 mM EDTA, 5 µM phallicidin, and protease inhibitory cocktail) with agitation for 20 min at 4°C. Soluble (membrane) fraction was collected, and protein material remaining on dish (nuclear/cytoskeletal fraction) was scraped in SDS buffer (0.5% Triton X-100, 0.5% SDS, 10 mM Tris · HCl, pH 6.8, and protease inhibitory cocktail), shortly sonicated (3 times), and boiled at 100°C for 5 min. Aliquots of samples from subcellular fractions were used for measurements of protein concentration by BCA assay (Pierce, Rockford, IL). Equal protein amounts of samples were subjected onto SDS-PAGE, transferred to nitrocellulose, and tested by Western immunoblotting with specific antibodies.
Immunofluorescence microscopy. Immunofluorescence microscopy studies were performed as we have previously described (18). After being treated, endothelial cells grown on gelatinized coverslips were rinsed with PBS, fixed in 3.7% paraformaldehyde for 10 min, and permeabilized with 0.2% Triton X-100 for 10 min. Cells were then washed with PBS, blocked with PBS-Tween 20 (0.5%; PBS-T) containing 2% BSA for 30 min, and incubated with primary antibodies. After being washed with PBS-T, cells were incubated with corresponding fluorochrome-conjugated secondary antibodies and 1 U/ml of Texas red-X phalloidin (Molecular Probes, Eugene, OR). Coverslips were mounted on slides with Slow-Fade mounting medium (Molecular Probes) and analyzed using a Nikon Eclipse TE 300 microscope. Images were captured by Sony Digital Photo camera DKC 5000.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
We have previously demonstrated thrombin to potently increase
Ca2+ and the activity of the
Ca2+/CaM-dependent protein kinase II
(5,
19). To explore whether
thrombin-induced ERK activation is a downstream event of CaM kinase II
activities (1,
33), endothelial cells were
pretreated with KN-93, a specific CaM kinase II inhibitor (10 µM, 30 min),
and challenged with thrombin (100 nM, 5 min). As shown in
Fig. 3, A and
C, thrombin-induced ERK activation was attenuated by
KN-93 pretreatment, indicating that ERK activation lies downstream of the CaM
kinase signaling cascade. Additional experiments using KN-92, an inactive
analog of KN-93, showed that pretreatment with KN-93 (10 µM, 30 min) but
not with KN-92 (10 µM, 30 min) attenuates thrombin-induced ERK activation
(data not presented). To confirm this linkage between CaM kinase II and ERK
activation, we infected bovine pulmonary artery endothelial cells with either
adenoviral-based constitutively active -CaM kinase II or empty vector
constructs at
20 MOI and analyzed our results after 30 h. As shown in
Fig. 3, B and
D, constitutively active CaM kinase II produced sustained
ERK activation, whereas the empty vector construct failed to do so. Together,
these results show that in bovine macrovascular endothelium, thrombin induces
substantial ERK activation in a time-dependent manner and that ERK activation
lies downstream of CaM kinase II activities.
|
Role of CaM kinase II and ERK activities in thrombin-induced endothelial cell barrier dysfunction, MLC phosphorylation, and actin stress fiber formation. We have previously shown that inhibition of CaM kinase II activation attenuates thrombin-induced endothelial cell permeability (5). Taking into account the linkage between CaM kinase II and ERK activities, we next examined whether ERK inhibition attenuates thrombin-induced decreases in electrical resistance across bovine endothelial cell monolayers. Confluent bovine pulmonary artery endothelial cells grown on gold microelectrodes to measure transendothelial electrical resistance were pretreated with U0126 (10 µM) and, after stabilization, treated with thrombin (100 nM). As shown in Fig. 4A, MEK inhibition with U0126 attenuates the magnitude of the decline in electrical resistance induced by thrombin as well as delays the onset of barrier dysfunction. We have previously demonstrated that thrombin-induced permeability involves MLCK-dependent actomyosin interaction. To investigate the role of ERK activation in this mechanism, we assessed the potential activation of MLCK by ERK after thrombin. Confluent bovine pulmonary artery endothelial cells pretreated with U0126 (10 µM, 30 min) and treated with thrombin (100 nM, 10 min) were subjected to SDS-PAGE, followed by Western immunoblotting with diphospho-MLC-specific antibodies. Significant alterations in the level of diphosphorylated MLC species in the presence of ERK inhibition were not detected (Fig. 4, B and C), suggesting that ERK activation is not likely involved in MLCK-dependent thrombin-induced endothelial cell barrier dysfunction. Control experiments using U0124 (10 µM, 30 min), an inactive analog of U0126, also failed to alter the levels of MLC diphosphorylation (data not shown).
|
We next addressed whether the CaM kinase II/ERK pathway is actually
involved in the endothelial cell actin cytoskeletal changes that occur in
response to thrombin, using immunofluorescence microscopy analysis. Inhibition
of either CaM kinase II by KN-93 or ERK activation by U0126 significantly
attenuates thrombin-induced actin stress fiber formation
(Fig. 5), findings that are
consistent with the attenuation of thrombin-induced declines in electrical
resistance observed after either KN-93
(5) or U0126 pretreatment
(Fig. 4). However, infection of
bovine pulmonary artery endothelial cells with either constitutively active
-CaM kinase II or empty adenoviral construct did not produce actin
stress fiber formation (data not shown), suggesting that CaM kinase II
activities are necessary but not sufficient for actin cytoskeleton remodeling.
Collectively, these results indicate that thrombin-induced endothelial cell
permeability involves activation of the CaM kinase II-dependent ERK signaling
cascade, which modulates endothelial cell MLCK-independent actin stress fiber
formation.
|
Role of CaM kinase II and ERK activities in thrombin-induced caldesmon
phosphorylation and dissociation of caldesmon-myosin complex. We next
performed differential detergent subcellular fractionation of
thrombin-stimulated bovine pulmonary artery endothelial cells as described in
MATERIALS AND METHODS. Thrombin (100 nM, 10 min) induced
translocation of caldesmon from cytosol to membrane/cytoskeletal fractions
(Fig. 6, A and
E), consistent with the observed colocalization of
caldesmon with stress fibers formed in nonmuscle cells
(7,
55). To determine whether
caldesmon represents a target for the CaM kinase II/ERK signaling pathway
relevant to the thrombin model of endothelial cell permeability, confluent
32P-labeled endothelial cells were pretreated with either KN-93 (10
µM, 30 min) or U0126 (10 µM, 30 min) and challenged with thrombin (100
nM, 10 min), followed by caldesmon immunoprecipitation. As shown in
Fig. 6 (B and
F), thrombin-induced caldesmon phosphorylation was attenuated by both
CaM kinase II and ERK inhibition. Site-specific phosphorylation of caldesmon
by ERK was tested using antibodies specific to the conserved ERK-dependent
phosphorylation sites on mammalian caldesmon (Ser759 and
Ser789, based on the human high-molecular-weight caldesmon
sequence) (29). Caldesmon
phosphorylation at Ser759 was not detected, whereas phosphorylation
at Ser789 was induced by thrombin and abolished by U0126
pretreatment (Fig. 6, C and
H), confirming phosphorylation of the
low-molecular-weight caldesmon isoform by ERK in thrombin-challenged
macrovascular bovine endothelium. Moreover, thrombin-induced caldesmon
phosphorylation at Ser789 was attenuated by pretreatment with KN-93
(10 µM, 30 min) but not by pretreatment with its inactive analog KN-92 (10
µM, 30 min). In addition, CaM kinase II/ERK-dependent caldesmon
phosphorylation at Ser789 was confirmed by endothelial cell
infection with recombinant adenovirus encoding constitutively active
-CaM kinase II. Constitutively active, but not empty vector adenovirus,
induced sustained ERK activation and ERK-dependent caldesmon phosphorylation
at Ser789 (Fig. 6, D
and H). Given that caldesmon phosphorylation appears
important to stress fiber formation (Fig.
5), we next identified the intracellular distribution of caldesmon
phosphorylated at the Ser789 site in resting cells and after
thrombin challenge by immunofluorescence microscopic analysis. As shown in
Fig. 7, in nonstimulated cells,
phosphocaldesmon is diffusely distributed, with intense nucleus staining
(where phospho-ERK is found; see Fig.
2). In contrast, in thrombin-stimulated endothelium,
phosphocaldesmon is prominently colocalized with actin stress fibers, again
consistent with a role of phosphorylated caldesmon in stress fiber formation.
In smooth muscle, phosphorylation of caldesmon by CaM kinase II reverses
inhibition of actin-tropomyosin-activated myosin ATPase activity and prevents
the binding of myosin to caldesmon
(39,
40,
47). We next verified in
nonstimulated resting bovine endothelium that myosin is present in caldesmon
nondenaturing immunoprecipitates (Fig.
8). Thrombin (100 nM, 10 min) produces a loss of myosin in
caldesmon immunoprecipitates consistent with marked dissociation of the
caldesmon-myosin complex (Fig.
8). Interestingly, caldesmon binding to myosin was restored in
thrombin-stimulated cells by pretreatment with either KN-93 or U0126
(Fig. 8). Assuming the
postulated importance of caldesmon-myosin and caldesmon-actin interactions for
tethering actin to myosin, weakening of caldesmonmyosin interaction due to
caldesmon phosphorylation catalyzed by either CaM kinase II or ERK should lead
to disinhibition of myosin ATPase activity and increased actomyosin
interaction and facilitate thrombin-induced stress fiber formation and
declines in electrical resistance (Figs.
4A and
5). Together, these results
suggest a role for caldesmon phosphorylation in stress fiber formation and
modulation of endothelial cell permeability.
|
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
In general, MAPK activity is regulated through three-tiered cascades
involving MEK kinase (which may be activated by small GTP-binding proteins),
MEK, and MAPK (45). We
previously demonstrated that phorbol ester-induced ERK activation in
endothelial cells occurs via a signaling cascade containing
Ras-Raf1-MEK1/2-ERK1/2, a sequence that represents a
Ca2+-independent pathway of ERK activation
(50), although ERK activation
via Ca2+-dependent mechanisms is also reported
(1). We have also shown that
thrombin induces Ca2+ elevation
(19) and activation of CaM
kinase II (5), a
multifunctional serine/threonine kinase mediating numerous
Ca2+-dependent signaling mechanisms
(6). Therefore, we tested the
possibility that CaM kinase II mediates thrombin-induced ERK activation in
endothelial cells. Pharmacological inhibition of CaM kinase II demonstrated
that ERK1/2 activation is dependent on the activation of CaM kinase II, a
finding confirmed by endothelial cell infection with a constitutively active
adenoviral -CaM kinase II construct. Although the mode of action of CaM
kinase II in ERK activation is largely unknown, these results suggest that
Ca2+-dependent regulation of endothelial cell
permeability may be mediated by CaM kinase II/ERK activation. Indeed,
measurements of transendothelial electrical resistance indicate that
inhibition of either CaM kinase II or ERK activation attenuates
thrombininduced decreases in electrical resistance (Ref.
5 and present study), which is
consistent with the above linkage between CaM kinase II and ERK.
Our previous results demonstrated that CaM kinase II activities do not significantly alter the levels of MLC phosphorylation in thrombin-stimulated endothelial cells, supporting the putative role for CaM kinase II in MLCK-independent contractile regulation and permeability (5). Similarly, our present data fail to demonstrate significant changes in thrombin-induced MLC diphosphorylation levels due to ERK inhibition. Although we again speculate that CaM kinase II/ERK activities alter endothelial cell permeability in an MLCK-independent fashion, we cannot completely exclude any interrelationship between CaM kinase II, ERK, and MLCK activities, since it was shown that smooth muscle MLCK activity may be regulated by ERK phosphorylation (34, 38). In addition, phosphorylation of MLCK by CaM kinase II may either lead to a decrease in Ca2+ sensitivity of MLC phosphorylation (48, 49) or exert a stimulatory effect on smooth muscle force development and maintenance of tension (33, 44). Whether this posttranslation mechanism exists for the endothelial cell MLCK isoform, which we have recently defined to be modified by both Ser/Thr (17) and Tyr phosphorylation (4), is largely unknown.
Caldesmon is an important regulatory protein of smooth muscle and nonmuscle
contraction (46) with
tissue-specific localization. In smooth muscle, caldesmon is found in thin
filaments, whereas in nonmuscle cells, it is a component of stress fibers
(7,
55). Stress fibers have been
shown to be truly contractile organelles of nonmuscle cells, containing actin,
myosin, -actinin, calmodulin, MLCK, and focal adhesion proteins
(32), an environment where
caldesmon may exert its structural and functional properties, such as
actomyosin cross-linking and regulation of actin-activated myosin ATPase
activity. Assembled stress fibers are presumed to be under tension
(31), thus exhibiting
actomyosin interaction. Therefore, during stress fiber formation, caldesmon
should be preferably recruited in phosphorylated or in
Ca2+/calmodulin-bound form, which is in accordance with
our data demonstrating caldesmon phosphorylation and its translocation to the
cytoskeletal fraction after thrombin treatment. Thrombin-stimulated
endothelial cells show prominent stress fiber formation, leading (as proposed)
to increased permeability via cell contraction and formation of intercellular
gaps (11,
15). Our results demonstrate
that inhibition of CaM kinase II/ERK activities partially attenuates
thrombin-induced permeability as well as thrombin-induced stress fiber
formation, indicating the important role for CaM kinase II and ERK in stress
fiber formation and endothelial cell permeability. These results as well as
colocalization of phosphocaldesmon within stress fibers also suggest the
importance of CaM kinase II/ERK-dependent phosphorylation of caldesmon for
stress fiber assembly.
It has been previously demonstrated that phosphorylation of smooth muscle caldesmon by CaM kinase II occurs at multiple sites, including NH2- and COOH-terminal sites, which leads to disinhibition of actin-activated myosin ATPase activity and prevents caldesmon-myosin interaction (39, 40, 47). It has been suggested that phosphorylation of caldesmon within the strong myosin-binding NH2-terminal domain (35, 37, 46, 51) results in steric changes that prevent caldesmon-myosin interaction, thereby allowing actomyosin cross-bridge cycling to occur. We propose that these properties facilitate recruitment of caldesmon phosphorylated by CaM kinase II into the forming stress fiber, whereas inhibition of CaM kinase II should have the opposite effect. ERK-dependent phosphorylation of mammalian caldesmons occurs within highly conservative sequences at two major sites, Ser759 and Ser789 (2, 9), based on the numbering of human high-molecular-weight caldesmon (29), although additional ERK-dependent phosphorylation sites have not been excluded (9). Our results suggest that ERK-dependent phosphorylation sites are important for caldesmonmyosin interaction. The relatively weak myosin-binding site that exists in the COOH-terminal part of caldesmon (28, 56) contains the known ERK-dependent phosphorylation sites and thus may affect caldesmon-myosin interaction within the COOH terminus. In a manner analogous to caldesmon-myosin interaction within the NH2-terminal domain, dissociation of myosin from the COOH-terminal portion of the caldesmon molecule should potentiate actomyosin interaction, whereas ERK inhibition should reverse this effect. The role of ERK-dependent caldesmon phosphorylation in the regulation of actomyosin interaction, however, is controversial (10, 21, 22, 24, 41, 52) with potential variables, including different laboratory techniques, tissue and species specificity, source of enzyme, or different inhibitory activities of caldesmon, depending on its phosphorylation status. In addition, because the localization of ERK-dependent phosphorylation sites is within the relatively weak COOH-terminal myosinbinding site, the effect of ERK-dependent caldesmon phosphorylation on actomyosin interaction should be less than the phosphorylation of amino acid residues that affect the NH2-terminal myosin-binding site. Nevertheless, together, these studies provide further mechanistic evidence for the regulatory role for CaM kinase II/ERK signaling cascade in the thrombin model of endothelial cell permeability and implicate novel MLCK-independent mechanisms of nonmuscle cytoskeletal regulation via CaM kinase II/ERK-dependent stress fiber formation and caldesmon phosphorylation.
![]() |
ACKNOWLEDGMENTS |
---|
This work was supported by National Heart, Lung, and Blood Institute Grants HL-50533, HL-58064, HL-57402, HL-67307, and HL-68062, the Dr. David Marine Endowment, and the American Heart Association.
![]() |
FOOTNOTES |
---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|